BCR-ABL
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP (NCT04155411) | Shenzhen Second People's Hospital | 2019-12-01 |
Track BCR-ABL automatically
Every clearance here is in the API, with alerts when new ones post.